110
Participants
Start Date
August 31, 2003
Primary Completion Date
April 30, 2007
Study Completion Date
June 30, 2007
MEDI--522
IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
Integrin + Dacarbazine
supplied in other formulations
Memorial Sloan-Kettering Cancer Center, New York
HemOnc Care, P.C., Brooklyn
University of Pittsburgh Cancer Institute, Pittsburgh
Thomas Jefferson University, Philadelphia
Johns Hopkins University - SKCC at Johns Hopkins, Lutherville
UNC-Chapel Hill, Chapel Hill
Blumenthal Cancer Center, Charlotte
Winship Cancer Institute of Emory University, Atlanta
University of Miami, Miami
Vanderbilt University Medical Center, Nashville
Indiana Oncology Hematology Consultants, Indianapolis
Indiana University Medical Center, Indianapolis
Oncology Specialists, S.C., Park Ridge
The Melanoma Center of St. Louis, St Louis
Kansas City Oncology & Hematology Group, Kansas City
Discovery Alliance, Houston
The University of Texas, MD Anderson Cancer Center, Houston
Mayo Clinic Arizona, Scottsdale
Cancer Institute Medical Group, Santa Monica
Pacific Shores Medical Group, Long Beach
Medical Group of North County, Vista
Saint Francis Memorial Hospital, San Francisco
Providence Portland Medical Center, Portland
Yale University School of Medicine, New Haven
Boston Medical Center, Boston
Lead Sponsor
MedImmune LLC
INDUSTRY